Randomized clinical trials support the use of everolimus, an inhibitor of the mammalian target of rapamycin, in the treatment of subependymal giant cell astrocytomas (SEGA), RAML and seizure related to TSC in western populations [8, 14, 15]. This evidence concerns the gene MTOR and tuberous sclerosis.